{"prompt": "['Date: June 30, 2020', 'Principal Investigator: James Black', 'Application Number: IRB00075706', 'target vessel sizes. All other connections in the device make use of sizes that are the same, independent of', 'patient anatomy.', 'The deployment of this device is also independent of device alignment. Angular alignment of the', 'thoracic bifurcation and the visceral manifold has very little impact on the outcome of the case.', 'Longitudinal alignment is more important, but a safety factor has been built-in by calling for the distal ends', 'of the visceral manifold to be deployed above their target vessels by 1-2 cm. The longitudinal landing', 'should be optimized so that the graft is not landed too low so that the connection with the visceral vessels is', 'challenging to make.', 'M', 'm', 'Figure 2: Assembly drawing showing the thoracic bifurcation, the', 'visceral manifold, the branch stents, and the infrarenal grafts, all', 'deployed within an idealized aneurysm sketch.', 'Intended Use/Indications for Use', 'The Valiant Thoracoabdominal Stent Graft System is indicated for the endovascular treatment of', 'thoracoabdominal aortic aneurysm (Crawford Type 1, 2, 3 and5) in patients with the following', 'characteristics:', 'An aneurysm with a maximum diameter of > 5.5 cm or 2 times the normal diameter just proximal to', 'the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements', 'Aneurysm with a history of growth > 0.5 cm in 6 months', 'Saccular aneurysm deemed at significant risk for rupture', 'Symptomatic aneurysm greater than or equal to 4.5 cm', 'Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular', 'access techniques, devices or accessories, with or without use of a surgical conduit', 'Proximal landing zone for the thoracic bifurcation stent graft that has:', 'Version 4.0', 'Page 19 of 54']['Date: June 30, 2020', 'Principal Investigator: James Black', 'Application Number: IRB00075706', '> 2.5 cm of healthy/nondiseased tissue including both native tissue and previously', 'placed graft, (neck) distal to the left subclavian artery (LSA) with a diameter in the range', 'of 26-42 mm', 'Adequate distance from the celiac artery, in order to accommodate cannulation from the', 'antegrade access point when considering the total deployed length of the thoracic', 'bifurcation and visceral manifold', 'Iliac artery or aortic distal fixation site, including both native tissue and previously placed graft,', 'greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm', 'Age: > 18 years old', 'Life expectancy: > 1 year', 'Reference to Regulatory Submissions for Nonclinical Testing Information', 'This device is currently under clinical investigation in the United States under IDE #G140207. The', 'proposed device is manufactured and tested by Medtronic. Non-clinical data to support the investigational', 'device is listed in the Medtronic Valiant Thoracoabdominal Stent Graft System Master File, MAF-2551.', 'Summary of Nonclinical Information to Support Study Initiation', 'All non-clinical testing to support the manufactured device was performed by Medtronic and is', 'reported in the Valiant Thoracoabdominal Stent Graft System Master File, MAF-2551.', 'Rationale for the Selection of Tests', 'The rationale for the selection of tests is described in a device evaluation strategy table describing', 'the Valiant Thoracoabdominal Stent Graft System as a whole. This device evaluation strategy table', 'describes the device procedure, performance, and basic safety-related attributes and addresses the potential', 'failure modes and subsequent clinical mitigation strategies for the proposed investigational device. This is', 'attached in Appendices.', 'Report of Prior Investigations Synopsis', 'The outcomes from prior clinical evaluation of the study device, including successfully treating', '99% (84/85) of the intended target vessels and 96% (27/28) limb patency observed at one year, demonstrate', \"the potential benefits of the device. When contrasted with open repair's significant complication rates and\", \"branch fenestrated device's significant anatomic and logistic limitations, the potential risk of the proposed\", 'novel graft does not outweigh the potential benefit of widened anatomic availability and improved patency', 'rates. Given the potential benefits, we feel that it is justified to expose the target patient population to the', 'potential risk. The non-clinical testing performed by Medtronic and the clinical results reported by Sanford', 'Health show adequate safety of the device to support a durable comparison of longitudinal cost and patient', 'centered outcomes for patients treated with the Medtronic Valiant Thoracoabdominal Stent Graft System,', 'and provide a valid comparison of open and endovascular surgical outcomes for TAAA patients.', 'Version 4.0', 'Page 20 of 54']\n\n###\n\n", "completion": "END"}